Marinos Velarde Alejandro, Alvarenga Thiebaud Julio, Madanat Yazan, Toor Amir
Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Curr Oncol. 2025 Jul 1;32(7):381. doi: 10.3390/curroncol32070381.
Despite significant advancements in the treatment of acute myeloid leukemia (AML), hematopoietic stem cell transplantation (HSCT) remains the only curative option for patients with primary refractory AML, those with relapsed disease and for patients who are in first complete remission where the disease has high risk cytogenetic and/or molecular features that increase relapse risk [...].
尽管急性髓系白血病(AML)的治疗取得了重大进展,但造血干细胞移植(HSCT)仍然是原发性难治性AML患者、复发疾病患者以及首次完全缓解但疾病具有高风险细胞遗传学和/或分子特征且增加复发风险的患者的唯一治愈选择[……]